Your browser is no longer supported. Please, upgrade your browser.
Metacrine, Inc.
Index- P/E- EPS (ttm)-1.44 Insider Own21.59% Shs Outstand26.15M Perf Week-14.59%
Market Cap116.77M Forward P/E- EPS next Y-2.15 Insider Trans0.00% Shs Float20.34M Perf Month-44.65%
Income-37.30M PEG- EPS next Q-0.51 Inst Own62.80% Short Float0.77% Perf Quarter-50.11%
Sales- P/S- EPS this Y-28.70% Inst Trans19.73% Short Ratio2.27 Perf Half Y-59.58%
Book/sh3.41 P/B1.30 EPS next Y3.60% ROA- Target Price- Perf Year-
Cash/sh3.67 P/C1.21 EPS next 5Y- ROE- 52W Range4.59 - 16.19 Perf YTD-43.38%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-72.51% Beta-
Dividend %- Quick Ratio25.30 Sales past 5Y- Gross Margin- 52W Low-3.05% ATR0.47
Employees35 Current Ratio25.30 Sales Q/Q- Oper. Margin- RSI (14)14.76 Volatility6.69% 7.28%
OptionableNo Debt/Eq0.00 EPS Q/Q18.00% Profit Margin- Rel Volume1.73 Prev Close4.61
ShortableYes LT Debt/Eq0.11 EarningsMar 18 BMO Payout- Avg Volume68.99K Price4.45
Recom1.50 SMA20-28.29% SMA50-44.40% SMA200-49.71% Volume119,344 Change-3.47%
Oct-12-20Initiated RBC Capital Mkts Outperform $25
Oct-12-20Initiated Jefferies Buy
Oct-12-20Initiated Canaccord Genuity Buy
Apr-05-21 04:05PM  
Mar-18-21 06:30AM  
Mar-11-21 06:30AM  
Mar-09-21 06:30AM  
Mar-02-21 06:30AM  
Feb-19-21 06:30AM  
Feb-16-21 06:30AM  
Jan-19-21 06:30AM  
Jan-05-21 06:30AM  
Dec-17-20 06:30AM  
Dec-16-20 02:23AM  
Dec-07-20 11:05PM  
Nov-23-20 06:30AM  
Nov-12-20 06:30AM  
Oct-02-20 08:00PM  
Oct-01-20 04:01PM  
Sep-15-20 09:52PM  
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases. It is developing MET409 that has completed Phase 1b proof-of-concept clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH); and is in Phase 2a clinical trial in combination with empagliflozin for the treatment of patients with type 2 diabetes mellitus and NASH. The company also develops MET642, which is in Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis patients. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.